Bojanovski D, Gregg R E, Brewer H B
J Biol Chem. 1984 May 25;259(10):6049-51.
Tangier disease is a disorder characterized by low levels of apo-A-I and high density lipoproteins. The defect in Tangier disease is an abnormal A-I apolipo protein, designated apo-A- ITangier . In normal subjects, apo-A-I is secreted as proapo -A-I with subsequent extracellular conversion to mature apo-A-I. The major form in normal plasma is mature apo-A-I with small amounts of proapo -A-I. In Tangier disease, proapo -A- ITangier is present in roughly equivalent concentrations compared to mature apo-A- ITangier . It has been proposed that the defect in Tangier disease is in the conversion of pro- to mature apo-A- ITangier . To test this, proapo -A-I was isolated from normal and Tangier subjects, and the conversion to the mature form by plasma from normal and Tangier subjects was analyzed. Incubation of radiolabeled normal proapo -A-I in normal plasma anticoagulated with heparin was associated with progressive conversion to mature apo-A-I over 24 h (initially 85% of the radioactivity was in the proapo -A-I isoform; at 24 h 33% radioactivity remained in the pro-isoform). Proapo -A- ITangier was also converted to the mature isoform during 24 h of incubation in normal plasma. Initially, 84% of radioactivity was in proapo -A- ITangier , and by 24 h the radioactivity in this isoprotein had decreased to 36%. A similar pattern of conversion was also observed when proapo -A- ITangier was incubated in Tangier plasma. The proteolytic conversion of both normal proapo -A-I and proapo -A- ITangier was unaffected by the serine protease inhibitors phenylmethylsulfonyl fluoride (1 mM) or aprotinin (200 Kallikrein-inactivating units/ml), but was inhibited by EDTA (0.1%). These results indicate that proapo -A- ITangier can be converted to mature apo-A- ITangier by the converting enzyme in normal plasma. In addition, plasma from a Tangier subject can convert both normal and Tangier proapo -A-I to the mature form. These results establish that proapo -A- ITangier can be rapidly converted to mature apo-A- ITangier , and there is no deficiency of the converting enzyme activity in Tangier disease.
丹吉尔病是一种以载脂蛋白A-I和高密度脂蛋白水平降低为特征的疾病。丹吉尔病的缺陷在于一种异常的载脂蛋白A-I,称为载脂蛋白A-I丹吉尔型。在正常受试者中,载脂蛋白A-I以载脂蛋白原A-I的形式分泌,随后在细胞外转化为成熟的载脂蛋白A-I。正常血浆中的主要形式是成熟的载脂蛋白A-I,伴有少量的载脂蛋白原A-I。在丹吉尔病中,载脂蛋白原A-I丹吉尔型与成熟的载脂蛋白A-I丹吉尔型的浓度大致相当。有人提出,丹吉尔病的缺陷在于载脂蛋白原A-I丹吉尔型向成熟型的转化。为了验证这一点,从正常人和丹吉尔病患者中分离出载脂蛋白原A-I,并分析了正常人和丹吉尔病患者血浆将其转化为成熟形式的情况。用肝素抗凝的正常血浆中孵育放射性标记的正常载脂蛋白原A-I,在24小时内会逐渐转化为成熟的载脂蛋白A-I(最初85%的放射性存在于载脂蛋白原A-I异构体中;24小时时33%的放射性仍存在于前体异构体中)。载脂蛋白原A-I丹吉尔型在正常血浆中孵育24小时期间也会转化为成熟异构体。最初,84%的放射性存在于载脂蛋白原A-I丹吉尔型中,到24小时时,这种同型蛋白中的放射性已降至36%。当载脂蛋白原A-I丹吉尔型在丹吉尔病患者血浆中孵育时,也观察到了类似的转化模式。正常载脂蛋白原A-I和载脂蛋白原A-I丹吉尔型的蛋白水解转化不受丝氨酸蛋白酶抑制剂苯甲基磺酰氟(1 mM)或抑肽酶(200激肽释放酶灭活单位/毫升)的影响,但受到EDTA(0.1%)的抑制。这些结果表明,载脂蛋白原A-I丹吉尔型可被正常血浆中的转化酶转化为成熟的载脂蛋白A-I丹吉尔型。此外,丹吉尔病患者的血浆可将正常和丹吉尔病患者的载脂蛋白原A-I都转化为成熟形式。这些结果证实,载脂蛋白原A-I丹吉尔型可迅速转化为成熟的载脂蛋白A-I丹吉尔型,且丹吉尔病中不存在转化酶活性缺乏的情况。